Press

Invitation to presentation of Acarix´s first quarter report

10 May

Acarix will publish its first quarter results on Thursday 11 May 2023 at 08.00 am (CEST). A live webcast will be held at 14.00 (CEST) the same day, where CEO Helen Ljungdahl Round and CFO Christian Lindholm will present the report. The presentation ends with a Q&A together with Redeye's analysts, where you can ask the company questions via the form on the live page.

The webcast will be available at https://www.redeye.se/events/895520/live-q-acarix-4
The presentation will be available at https://www.acarix.com/for-investors/investor-presentations 
after the webcast.

For more information contact:
Helen Ljungdahl Round, CEO, phone +1 267 809 1225, +46 730 770283, email helen.round@acarix.com 
Christian Lindholm, CFO, phone +46 705 118333, email christian.lindholm@acarix.com

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor System uses advanced acoustics and AI-technology to rule out CAD non-invasively in less than 10 minutes, with at least 96% certainty. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, certifiedadviser@redeye.se) is Certified Advisor of Acarix. For more information, please visit www.acarix.com. 

Attachments
Invitation to presentation of Acarix´s first quarter report

Newer Acarix to present Q1 2023 Report
Back to list
Older Acarix to present at Redeye Medtech Event